Dehaier Medical Systems Ltd, a company in development, assembly, marketing, and sale of medical devices and sleep respiratory products in China, received approval from the China Food and Drug Administration (CFDA) for its Morpheus Ox software.
Dehaier Medical applied to the CFDA to register the Morpheus Ox in July 2013. With completion of this registration, it has collected all certifications for four key components of Dehaier’s Sleep Respiratory Solutions: the second generation DHR998 Sleep Diagnostic Device, photoplethysmography (PPG) sensor, sleep diagnostic software, and CPAP ventilator in order to establish a comprehensive product line for obstructive sleep apnea, the company says in a release. Dehaier’s Morpheus Ox products assist with the diagnosis of sleep apnea, provide treatment options to apnea patients, and allow post-treatment evaluation services to pinpoint further opportunities for improvement.
Dehaier chairman and CEO Ping Chen says in a release, “We are confident that China’s sleep respiratory market, which is still at an early stage of development, has tremendous growth potential and that our products position us well to increase market share. Our comprehensive line of products focused on disease diagnosis, treatment, and curative effect evaluation provide a one-stop solution to meet market demand. After the receipt of the fourth registration certificate for our Morpheus Ox product line, we are ready to launch the solution for sale. We showcased the Morpheus Ox System and workstation at the 2014 Third Annual Jiangxi Sleep Medicine Seminar from May 30 to 31, 2014. Based on our marketing campaign during the past couple months, we are excited to see strong interest from a variety of hospitals and physical examination centers. We are beginning to further our marketing and sales activities for our sleep respiratory products nationwide, and we expect our sleep respiratory business will grow through the rest of 2014 as we move toward mobile health care and telemedicine.”